|
KMID : 0378019900330010092
|
|
New Medical Journal
1990 Volume.33 No. 1 p.92 ~ p.98
|
|
|
A Clinical Study on the Antihypertensive Effect of Doxazosin
|
|
|
|
|
Abstract
|
|
|
It has been demonstrated that the effective pharmacologic control of hypertension prevents the hypertension related cardiovascular complications such as stroke, heart failure, renal failure, and aortic dissection, However, the evidence that it prevents coronary artery disease is lacking. Adverse effect of antihypertensive drugs on lipid metabolism off-setting their benef`ial blood pressure-lowering effects has been proposed as a possible explanation for the lack of benefit in preventing coronary antery disease and
actively studied.
Doxazosin, a quinazoline derivative like prazosin, is a newly developed a-1 inhibitor, which is known for the unique antihypertensive with beneficial effects on blood lipid metabolism.
The present study was designed to evaluate the antihypertensive efficacy, safety, and tolerance of doxazosin monotherapy in essential hypertension.
Among 24 patients entered into this study, 21 patients (12 male, 9 female) were subjected for evaluation. Blood pressure (systolic/ diastolic)
was significantly lowered from baseline (172.4±14.1 / 101.7 ± 10.9mmHg) during 12 weeks´ study period: 146.9±15.5 / 90.7± 10.3mmHg after 4 weeks, 147.8 f 22.9 / 87.8 f 11.1mmHg after 8 weeks, and 143.0 f 12.5 / 87.5 f 9.8mmHg after 12 weeks (p<0.001, respectively). Mean reductions of blood pressure were 28.3/13.3 mmHg after 4 weeks, 27.2 / 15.3mmHg after 8
weeks, and 31.0 / 16.OmmHg afte 12 weeks. Hypotensive effect of doxazosin was demonstrated in 17 cases (81.0%): mild (DBP reducton, 10-19mmHg) in 9 cases (42.9%), moderate(DBP reduction, 20-29mmHg) in 6 cases(28. 6%), and marked (DBP reduction,>3OmmHg) in 2 cases (9.5%). In 14 patients (66.7 91o) diastolic blood pressure was controlled less than 90mmHg with a decrease of more an 10 mmHg.There was no significant change in heart rates and body weights except on whose body weight was
increased by 5Kg. Serum cholesterol was decreased from 197.2±2,,1.7 to 1 85.4±24.8mg / dl, but it was statistically insignificant. Nine patients (42.9%) experienced newly developed discomfortable symptoms. In 5 patients they disappeared during study period. Two patients were received an analgesic far headache. They were headache, 3), dizziness (3), facial puffiness (3), palpitation (2), nasal stuffiness (1); impotence (1), and wei ht gain (1).
Above results suggest that doxazosin could be prescribed as a first-line monother peduic agent in essential hypertension of any severity.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|